Heffernan Michael Thomas — SEC insider filings
SEC reporting owner CIK 1448914. 39 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 39 filings on record, filed 2020-08-12 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 6 filings — 401,231 shares, $8,839,725 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 79.
- Largest priced transaction: sale of 161,687 shares @ $22.16 ($3,582,984) in COLLEGIUM PHARMACEUTICAL, INC, filed 2022-12-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | Director | 10 | — | 12 legs · 361,758 sh · $8,243,919 | 31 |
| Trevi Therapeutics, Inc. (TRVI) | Director | 8 | — | 4 legs · 39,473 sh · $595,806 | 11 |
| Biohaven Ltd. (BHVN) | Director | 6 | — | — | 17 |
| Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Director | 5 | — | — | 9 |
| SYNLOGIC, INC. (SYBX) | Director | 4 | — | — | 4 |
| Avalo Therapeutics, Inc. (AVTX) | Director | 3 | — | — | 3 |
| Akebia Therapeutics, Inc. (AKBA) | Director | 1 | — | — | 2 |
| enGene Therapeutics Inc. (ENGN) | Director | 2 | — | — | 2 |
Insider filings — Heffernan Michael Thomas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Trevi Therapeutics, Inc. (TRVI) | Option exercise (M): 18,421 @ $3.04 · Sale (S): 18,321 @ $15.09 · Sale (S): 100 @ $15.88 · Option exercise (M): 21,052 @ $3.33 · Sale (S): 20,952 @ $15.09 · Sale (S): 100 @ $15.88 · +2 more | EDGAR |
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 68,693 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 31,716 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 4,820 @ $0 | EDGAR |
| 2024-06-14 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 7,693 @ $0 | EDGAR |
| 2024-05-02 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 16,592 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 9,792 @ $0 | EDGAR |
| 2023-05-04 | 4 | Biohaven Ltd. (BHVN) | Grant/award (A): 52,906 (derivative) @ $0 | EDGAR |
| 2022-12-27 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Option exercise (M): 237 @ $16.15 · Sale (S): 237 @ $23 · Option exercise (M): 4,989 @ $16.15 · Sale (S): 4,989 @ $23 · Option exercise (M): 15,995 @ $16.15 · Sale (S): 15,995 @ $23.63 · +6 more | EDGAR |
| 2022-12-21 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Option exercise (M): 3,606 @ $16.15 · Sale (S): 3,606 @ $23.04 · Option exercise (M): 33,758 @ $16.15 · Sale (S): 33,758 @ $23.08 · Option exercise (M): 46,600 @ $16.15 · Sale (S): 46,600 @ $23.11 · +3 more | EDGAR |
| 2022-12-14 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Option exercise (M): 10,669 @ $14.90 · Option exercise (M): 15,741 @ $15.27 · Option exercise (M): 1,510 @ $14.57 · Sale (S): 27,920 @ $22.01 · Option exercise (M): 59,524 @ $14.90 · Option exercise (M): 94,259 @ $15.27 · +8 more | EDGAR |
| 2022-10-12 | 4/A | Biohaven Ltd. (BHVN) | Tax withholding (F): 9,699 @ $7.50 | EDGAR |
| 2022-10-05 | 4 | Biohaven Ltd. (BHVN) | Other (J): 1,660 @ $0 · Option exercise (M): 4,119 @ $4.84 · Option exercise (M): 5,998 @ $3.56 · Option exercise (M): 13,100 @ $2.40 · Tax withholding (F): 5,507 @ $7.50 · Other (J): 4,119 (derivative) · +6 more | EDGAR |
| 2022-10-03 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Disposition to issuer (D): 3,320 (derivative) · Disposition to issuer (D): 8,239 (derivative) · Disposition to issuer (D): 11,996 (derivative) · Disposition to issuer (D): 26,200 (derivative) | EDGAR |
| 2022-07-01 | 4/A | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-23 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2022-05-23 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 14,035 @ $0 | EDGAR |
| 2022-04-29 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Grant/award (A): 8,239 (derivative) @ $0 | EDGAR |
| 2021-12-22 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Grant/award (A): 3,320 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | Akebia Therapeutics, Inc. (AKBA) | Grant/award (A): 13,700 @ $0 · Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2021-05-24 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Grant/award (A): 9,941 @ $0 | EDGAR |
| 2021-05-07 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Grant/award (A): 11,996 (derivative) @ $0 | EDGAR |
| 2021-03-26 | 4/A | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Grant/award (A): 26,200 (derivative) @ $0 · Grant/award (A): 0 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Sale (S): 47,044 @ $25.26 · Sale (S): 3,031 @ $25.88 | EDGAR |
| 2020-12-09 | 4 | SYNLOGIC, INC. (SYBX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2020-08-12 | 4 | COLLEGIUM PHARMACEUTICAL, INC (COLL) | Sale (S): 13,071 @ $19.13 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1448914 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs